← Leaderboards
Shirley Wang
Brigham And Women'S Hospital
$7,765,582
Attributed
$12,038,161
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2013–25$2.5M$1.9M$1.3M$625K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,188,188 · 5
AHRQ$1,051,594 · 2
FDA$798,379 · 1
By mechanism
R01$10,188,188 · 5
U01$798,379 · 1
R00$746,938 · 1
K99$304,656 · 1
Top collaborators
- Krista F Huybrechts9 shared
- Sebastian G. Schneeweiss4 shared
- William Brand Feldman2 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Krista F Huybrechts$10,039,261
- Sebastian G. Schneeweiss$14,258,306
- Brian Thomas Bateman$6,450,805
- Joshua K Lin$16,782,382
- Elisabetta Patorno$4,890,327
Others in their field
Top investigators on “Prospective”
- David R. Weir · University Of Michigan At Ann Arbor$228,258,249
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Lawrence Corey · Fred Hutchinson Cancer Center$198,594,425
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Mary M Horowitz · Medical College Of Wisconsin$137,744,651
- Judith S Hochman · New York University School Of Medicine$110,738,390
Research focus
ProspectivePharmaceutical PreparationsDatabasesResearch PersonnelSafetyEvaluationInnovationCohortTreatment EffectPublic HealthDesignCharacteristicsHealthcareInterestMarketingComplexSignal TransductionPatient PopulationMedication SafetyRandomizedAdverse EffectsReportingHeterogeneityNovel Therapeutics
Grant awards (26)
Active Surveillance of the Safety of Antipsychotic Medications in Pregnancy$532,996
R01 · FY2025 · HD
TreeScan to Evaluate the Safety of New Drugs in Pediatric Populations$512,645
R01 · FY2025 · HD · contact PI
The Safety of Switching Between Complex Branded and Generic Drugs: Developing a Semi-Automated Sequential Surveillance System Using Tree-Based Scan Statistics$499,957
U01 · FY2025 · FD · contact PI
Active Surveillance of the Safety of Antipsychotic Medications in Pregnancy$526,905
R01 · FY2024 · HD
TreeScan to Evaluate the Safety of New Drugs in Pediatric Populations$507,519
R01 · FY2024 · HD · contact PI
The Safety of Switching Between Complex Branded and Generic Drugs: Developing a Semi-Automated Sequential Surveillance System Using Tree-Based Scan Statistics$298,422
U01 · FY2024 · FD
Randomized Cardiovascular Trials Duplicated Using Prospective Longitudinal Insurance Claims: Applying Techniques of Epidemiology (RCT DUPLICATE)$713,351
R01 · FY2023 · HL · contact PI
TreeScan to Evaluate the Safety of New Drugs in Pediatric Populations$611,543
R01 · FY2023 · HD · contact PI
Active Surveillance of the Safety of Antipsychotic Medications in Pregnancy$532,996
R01 · FY2023 · HD
Randomized Cardiovascular Trials Duplicated Using Prospective Longitudinal Insurance Claims: Applying Techniques of Epidemiology (RCT DUPLICATE)$713,351
R01 · FY2022 · HL · contact PI
TreeScan to Evaluate the Safety of New Drugs in Pediatric Populations$626,758
R01 · FY2022 · HD · contact PI
Active Surveillance of the Safety of Antipsychotic Medications in Pregnancy$532,227
R01 · FY2022 · HD
Generalizing data from randomized trials to predict long-term treatment outcomes in older populations$463,316
R01 · FY2022 · AG · contact PI
Randomized Cardiovascular Trials Duplicated Using Prospective Longitudinal Insurance Claims: Applying Techniques of Epidemiology (RCT DUPLICATE)$691,871
R01 · FY2021 · HL · contact PI
Active Surveillance of the Safety of Antipsychotic Medications in Pregnancy$552,746
R01 · FY2021 · HD
Understanding effectiveness of new drugs in older adults shortly after market entry$365,645
R01 · FY2021 · AG · contact PI
Ethical Issues in Prescribing Drugs to Older Adults for Whom Representative Randomized Trial Data Is Lacking$178,384
R01 · FY2021 · AG · contact PI
Randomized Cardiovascular Trials Duplicated Using Prospective Longitudinal Insurance Claims: Applying Techniques of Epidemiology (RCT DUPLICATE)$691,871
R01 · FY2020 · HL · contact PI
Understanding effectiveness of new drugs in older adults shortly after market entry$364,106
R01 · FY2020 · AG · contact PI
Understanding effectiveness of new drugs in older adults shortly after market entry$362,566
R01 · FY2019 · AG · contact PI
Understanding effectiveness of new drugs in older adults shortly after market entry$707,392
R01 · FY2018 · AG · contact PI
Methods for studying treatment heterogeneity using large observational databases$248,999
R00 · FY2017 · HS · contact PI
Methods for studying treatment heterogeneity using large observational databases$248,999
R00 · FY2016 · HS · contact PI
Methods for studying treatment heterogeneity using large observational databases$248,940
R00 · FY2015 · HS · contact PI
Methods for studying treatment heterogeneity using large observational databases$152,928
K99 · FY2014 · HS · contact PI
Methods for studying treatment heterogeneity using large observational databases$151,728
K99 · FY2013 · HS · contact PI